Bimatoprost

Iz Wikipedije, slobodne enciklopedije
Bimatoprost
(IUPAC) ime
7-[3,5-dihidroksi-2- (3-hidroksi-5-fenil-pent-1-enil)- ciklopentil]-N-etil-hept-5-enamid
Klinički podaci
Robne marke Lumigan
AHFS/Drugs.com Monografija
MedlinePlus a602030
Identifikatori
CAS broj 155206-00-1
ATC kod S01EE03
PubChem[1][2] 5311027
DrugBank DB00905
ChemSpider[3] 4470565
UNII QXS94885MZ YesY
ChEBI CHEBI:51230 YesY
ChEMBL[4] CHEMBL1200963 YesY
Hemijski podaci
Formula C25H37NO4 
Mol. masa 415,566 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Licenca

US Daily Med:link

Trudnoća C(US)
Pravni status -only (SAD)
Način primene Topikalni (kapi za oči)

Bimatoprost (Lumigan) je analog prostaglandina. On je prolek koji se koristi topikalni (u obliku kapi za oči) za kontrolu progresa glaukoma i okularne hipertenzije. On redukuje intraokularni pristisak (IOP) putem povećanja odliva fluida iz očiju.[5] Poznato je da se koristi za produžavanje trepavica.[6] FDA je odobrila ovaj način primene decembra 2008. Kozmetička formulacija bimatoprosta je u prodaji pod imenom Latis.[7] Tokom perioda od 2008 - 2011, utvrđeno je da bimatoprost ima sposobnost redukovanja masnog tkiva.[8][9][10]

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.  edit
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  5. "Bimatoprost Ophthalmic". MedlinePlus. 1. 1. 2003.. Arhivirano iz originala 05. 10. 2007.. http://web.archive.org/web/20071005013222/http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a602030.html. pristupljeno 19. 11. 2007.. 
  6. Rundle, Rhonda L. (19. 11. 2007.). "Drug That Lengthens Eyelashes Sets Off Flutter". The Wall Street Journal. Pristupljeno 19. 11. 2007.. 
  7. "Allergan gets FDA approval for eyelash treatment". BusinessWeek. Associated Press. 26. 12. 2008. Pristupljeno 26. 12. 2008.. 
  8. Park J, Cho HK, Moon JI (2011). "Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.". Japanese Ophthalmological Society 55 (1): 22–27. PMID 21331688. doi:10.1007/s10384-010-0904-z. 
  9. Jayaprakasam A, Ghazi-Nouri S. (2010). "Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues.". Orbit 29 (6): 357–359. PMID 21158579. doi:10.3109/01676830.2010.527028. 
  10. Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. (2008). "Periorbital changes associated with topical bimatoprost.". Ophthalmology Plastic and Reconstructive Surgery 24 (4): 302–307. PMID 18645437. doi:10.1097/IOP.0b013e31817d81df. 

Literatura[uredi - уреди | uredi izvor]

  • Chen M, Cheng C, Chen Y, Chou C, Hsu W (2006). "Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma.". J Ocul Pharmacol Ther 22 (3): 188–93. PMID 16808680. doi:10.1089/jop.2006.22.188. 
  • Kruse P, Rieck P, Sherif Z, Liekfeld A (2006). "Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?". Klinische Monatsblätter für Augenheilkunde 223 (6): 534–7. PMID 16804825. doi:10.1055/s-2005-858992. 
  • Steinhäuser S (2006). "Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy.". Optometry 77 (4): 177–9. PMID 16567279. doi:10.1016/j.optm.2006.02.001. 
  • Park J, Cho HK, Moon JI (2011). "Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost.". Japanese Ophthalmological Society 55 (1): 22–27. PMID 21331688. doi:10.1007/s10384-010-0904-z. 
  • Jayaprakasam A, Ghazi-Nouri S. (2010). "Periorbital fat atrophy - an unfamiliar side effect of prostaglandin analogues.". Orbit 29 (6): 357–359. PMID 21158579. doi:10.3109/01676830.2010.527028. 
  • Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. (2008). "Periorbital changes associated with topical bimatoprost.". Ophthalmology Plastic and Reconstructive Surgery 24 (4): 302–307. PMID 18645437. doi:10.1097/IOP.0b013e31817d81df. 

Spoljašnje veze[uredi - уреди | uredi izvor]


Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).